Tempus AI

Tempus AI FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Tempus AI (TEM) as of Nov 20, 2026 is 100.13 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 29.92 % — a change of 234.69% (higher).

FCF Conversion

100.13 %

YoY

234.69%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Tempus AI is 2025 100.13 % . FCF Conversion Rate (FCF/EBITDA) of Tempus AI was 2024 29.92 % . It decreases by 234.69% higher compared to the previous year.

The Tempus AI FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
116.70 USD
Jan 1, 2020
104.82 USD
Jan 1, 2021
86.33 USD
Jan 1, 2022
64.38 USD
Jan 1, 2023
116.27 USD
Jan 1, 2024
29.92 USD
Jan 1, 2025
100.13 USD
The Tempus AI FCF Conversion history
YEARFCF ConversionYoY
100.13 %+234.69%
29.92 %-74.27%
116.27 %+80.59%
64.38 %-25.42%
86.33 %-17.65%
104.82 %-10.18%
116.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

FCF Conversion Rate (FCF/EBITDA) of Tempus AI is 100.13 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Tempus AI changed from 29.92 % to 100.13 %, representing a 234.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Tempus AI since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Tempus AI with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tempus AI

All Key Metrics — Tempus AI